Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI

AI justification

Closed-door regulatory process risks undermining transparency, equity, and public trust in clinical AI governance. | While stakeholder engagement is critical for effective AI regulation, the lack of transparency and inclusivity in these meetings risks prioritizing corporate interests over public health equity. The potential for regulatory capture and exclusion of marginalized voices outweighs the benefits of expedited innovation, particularly given the high stakes of clinical AI for patient righ